Overview
This is a single-center, prospective, randomized, controlled trial comparing pre-injection versus standard bolus administration of rocuronium bromide for general anesthesia induction. A total of 108 adult patients (18-65 years, ASA I-III) scheduled for elective surgery requiring endotracheal intubation will be enrolled and randomized 1:1 to either the pre-injection group or control group.
The pre-injection group will receive rocuronium 0.06 mg/kg as a priming dose followed by 0.54 mg/kg 3 minutes later. The control group will receive rocuronium 0.6 mg/kg as a single bolus. All patients will receive standardized anesthesia induction with midazolam and propofol.
The primary outcome is neuromuscular blockade onset time (seconds). Secondary outcomes include hemodynamic parameters (SBP, DBP, MAP, HR, CO, SV, SVR), injection pain incidence, and adverse events.
This study aims to investigate whether pre-injection of rocuronium can shorten neuromuscular blockade onset time while maintaining hemodynamic stability compared to standard bolus administration.
Eligibility
Inclusion Criteria:
- Aged from 18 to 65 years old
- American Society of Anesthesiologists (ASA) physical status classification Ⅰ, Ⅱ or Ⅲ
- Elective surgery requiring general anesthesia with tracheal intubation
- Able to understand the study and voluntarily sign written informed consent
- Male or female, no gender restriction
Exclusion Criteria:
- Severe hepatic dysfunction (ALT/AST \> 3 times the upper limit of normal) or renal dysfunction (creatinine \> 2 times the upper limit of normal)
- Central nervous system diseases or severe neuromuscular disorders
- Severe arrhythmia or cardiac dysfunction (NYHA class Ⅲ-Ⅳ, or ejection fraction EF \< 30%)
- Known hypersensitivity or allergy to rocuronium, midazolam, propofol or other study-related drugs
- Refusal to participate in this clinical trial
- Pregnant or breastfeeding women
- History of predicted difficult airway requiring awake tracheal intubation
- Contraindications to rapid sequence induction
